People with type 1 diabetes who intensely control their blood glucose levels shortly after diagnosis are prone to live more than those who do not, according to a recent report led by the Pittsburgh University School of Public Health, inThe United States, whose results are detailed in the magazine 'Journal of the American Medical Association'.
The data of a long observational and monitoring study financed by the National Institutes of Health (NIH)Deaths in the last decades among the participants who had good early control of blood glucose.
"Now we can say with confidence the doctors and patients that the good early control of blood glucose reduces the risk of early mortality in people with type 1 diabetes, which is generally diagnosed in young children and adults," says author Trevor Orchard,Professor of Epidemiology at the Pittsburg Public Health School."These results also eliminate any persistent concern that intensive therapy can lead to an increase in mortality," he adds.
The study for the control and complications of diabetes (DCCT) and the subsequent observational study of epidemiology of control and the complications of diabetes (Edic) have significantly modified treatment protocolsFor type 1 diabetes and the improvement of people's perspectives with the disease in the last decades, Griffin explains p.Rodgers, director of the National Institute of Diabetes and Digestive Diseases and the Nih kidney (Niddk).
"Thanks to findings in recent years since the milestone of DCCT/Edic studies, millions of people with diabetes can prevent or delay weakening and frequently mortal complications of the disease," Rodgers stands out."NIH's mission is to help improve life through biomedical research. These types of results provide evidence that what we help people live longer and have healthier lives," he adds.
Type 1 diabetes occurs when the body does not produce insulin, a hormone that is needed to convert energy into energy.By regularly monitoring their blood glucose levels and adjusting insulin doses, patients can work to keep blood glucose in a normal range.
1,441 volunteers
As of 1983, the DCCT involved 1,441 volunteers between the ages of 13 and 39 years with type 1 diabetes of recent appearance.Half was randomly assigned to intense efforts to maintain blood glucose, also known as blood sugar, as close to normal levels as possible;While the other half was assigned to the conventional treatment at the time, which simply tried to prevent glucose levels would go down or rise so much so that patients experience symptoms and blurred vision or difficulty breathing.
The analysis ended in 1993, when it was discovered that the intensive group had less problems in the eyes, nerves and renal.All participants were instructed in the intensive blood glucose control techniques and good early blood glucose control was recommended for all people with type 1 diabetes. Next, the EDIC study was launched to continue with theHealth monitoring of all participants.
Since 1983, 107 trial participants have died, with 64 in the group that originally received standard treatment, compared to 43 in the intensive treatment group.The most common causes of death were cardiovascular diseases by 22 percent;Cancer in 20 percent and acute diabetic complications in 18 percent, all more common in the group that originally received conventional treatment.
Accidents or suicide were the fourth most common cause of death by 17 percent.An average of the highest glucose level and an increase in proteins in the urine, a diabetic renal disease marker, were the main risk factors of death.
"These results are based on previous studies that suggest that the increase in proteins in the urine greatly explains the shortest life expectancy for people with type 1 diabetes," says Orcher."Our results emphasize the importance of good early glucose control, since this reduces the risk of an increase in urine protein, in general, as well as the diabetic renal disease itself," he adds.
Although this work detected a link between the intensive control of blood glucose and the decrease in mortality in people with type 1 diabetes, Dr. Orchard and his colleagues observed that the results cannot be extended to people with type 2 diabetes.Uncreated previous have shown contradictory results for type 2 diabetes.
(EuropePress)